Improved Long-term Expression from Helper Virus-free HSV-1 Vectors Packaged Using Combinations of Mutated HSV-1 Proteins that Include the UL13 Protein Kinase and Specific Components of the VP16 Transcriptional Complex by Liu, Meng et al.
 
Improved Long-term Expression from Helper Virus-free HSV-1
Vectors Packaged Using Combinations of Mutated HSV-1 Proteins
that Include the UL13 Protein Kinase and Specific Components of
the VP16 Transcriptional Complex
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Liu, Meng, Xiaodan Wang, and Alfred I. Geller. 2009. Improved
long-term expression from helper virus-free HSV-1 vectors
packaged using combinations of mutated HSV-1 proteins that
include the UL13 protein kinase and specific components of the
VP16 transcriptional complex. BMC Molecular Biology 10: 58.
Published Version doi:10.1186/1471-2199-10-58
Accessed February 19, 2015 7:10:40 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:4737454
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAABioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Molecular Biology
Open Access Methodology article
Improved long-term expression from helper virus-free HSV-1 
vectors packaged using combinations of mutated HSV-1 proteins 
that include the UL13 protein kinase and specific components of the 
VP16 transcriptional complex
Meng Liu, Xiaodan Wang and Alfred I Geller*
Address: Department of Neurology, West Roxbury VA Hospital/Harvard Medical School, W. Roxbury, MA 02132, USA
Email: Meng Liu - meng_liu@hms.harvard.edu; Xiaodan Wang - xiaodan_wang@hotmail.com; Alfred I Geller* - alfred_geller@hms.harvard.edu
* Corresponding author    
Abstract
Background: Herpes Simplex Virus (HSV-1) gene expression is thought to shut off recombinant
gene expression from HSV-1 vectors; however, in a helper virus-free HSV-1 vector system, a
number of promoters support only short-term expression. These results raise the paradox that
recombinant gene expression remains short-term even in the absence of almost all (~99%) of the
HSV-1 genome, HSV-1 genes, and HSV-1 gene expression. To resolve this paradox, we
hypothesized that specific proteins in the HSV-1 virus particle shut off recombinant gene
expression. In two earlier studies, we examined the effects on recombinant gene expression of
packaging vectors using specific mutated HSV-1 proteins. We found that vectors packaged using
mutated UL13 (a protein kinase), or VP16, or UL46 and/or UL47 (components of the VP16
transcriptional complex) supported improved long-term expression, and vectors packaged using
mutated UL46 and/or UL47 also supported improved gene transfer (numbers of cells at 4 days).
These results suggested the hypothesis that specific proteins in the HSV-1 particle act by multiple
pathways to reduce recombinant gene expression. To test this hypothesis, we examined
combinations of mutated proteins that included both UL13 and specific components of the VP16
transcriptional complex.
Results: A HSV-1 vector containing a neuronal-specific promoter was packaged using specific
combinations of mutated proteins, and the resulting vector stocks were tested in the rat striatum.
For supporting long-term expression, the preferred combination of mutated HSV-1 proteins was
mutated UL13, UL46, and UL47. Vectors packaged using this combination of mutated proteins
supported a higher efficiency of gene transfer and high levels expression for 3 months, the longest
time examined.
Conclusion: Vector particles containing this combination of mutated HSV-1 proteins improve
recombinant gene expression. Implications of these results for strategies to further improve long-
term expression are discussed. Moreover, long-term expression will benefit specific gene therapy
applications.
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Background
Herpes Simplex Virus (HSV-1) vectors are an attractive
system for gene transfer into neurons, but the limited lev-
els of long-term expression remain a significant problem.
The numbers of cells expressing recombinant gene prod-
ucts display large decreases within the first few weeks after
gene transfer, using either plasmid (amplicon) or recom-
binant HSV-1 vectors that contain specific viral or neuro-
nal-specific cellular promoters (reviewed in [1]).
Interestingly, using HSV-1 plasmid vectors, two neuronal
type-specific promoters (tyrosine hydroxylase (TH) or
preproenkephalin), and chimeric promoters that contain
5' upstream sequences from either of these promoters,
support significant levels of long-term expression (2–14
months) [1-8]. Although the levels of expression display a
significant initial decrease, long-term expression is rela-
tively stable. Consequently, identifying the mechanisms
responsible for the initial decrease in expression may pro-
vide a foundation for the rational design of HSV-1 vectors
that support long-term expression.
The reduction in recombinant gene expression might be
caused by the mechanisms that repress HSV-1 gene
expression in HSV-1 latency, focusing attention on HSV-1
gene regulation. Supporting a role for HSV-1 gene regula-
tion in reducing recombinant gene expression, helper
virus-containing HSV-1 vector systems cause significant
cytopathic effects and an inflammatory response, and
most of these side effects are caused by HSV-1 gene expres-
sion from the helper virus [9-11]. Consistent with these
results, helper virus-free HSV-1 vectors cause substantially
less side effects than those observed using helper virus-
containing systems [12,13]. However, helper virus-free
HSV-1 vectors support minimal, if any, improvement in
long-term expression, using a number of viral or neuro-
nal-specific cellular promoters [7,12]. Thus, paradoxi-
cally, expression from these promoters remains short-
term, even in the absence of almost all (~99%) of the
HSV-1 genome, the latency associated transcript (LAT)
gene, HSV-1 genes, and HSV-1 gene expression.
To explain this paradox, we proposed that specific pro-
teins in the HSV-1 particle reduce recombinant gene
expression [14]. Specific proteins in the HSV-1 particle
have prominent roles in the process of the virus taking
control of the cell's biosynthetic machinery (reviewed in
[15]). Thus, specific proteins in the HSV-1 particle might
alter recombinant gene expression. In an initial study, we
examined the effects on recombinant gene expression of
five proteins that affect the HSV-1 particle [14]. We found
that packaging vectors using a mutated vhs  or US11
resulted in minimal changes in recombinant gene expres-
sion; packaging vectors using a mutated US3 resulted in
improved gene transfer (number of cells at 4 days); and
packaging vectors using a mutated UL13, a protein kinase,
or VP16 supported long-term expression (2 months).
These results suggested the hypothesis that specific pro-
teins in the HSV-1 particle act by multiple pathways to
reduce recombinant gene expression. Thus, interfering
with multiple pathways might support higher levels of
recombinant gene expression than those obtained by
interfering with a single pathway. Specifically, packaging
vectors using both mutated UL13 and mutated VP16
might support higher levels of long-term expression than
those obtained by packaging vectors using either mutated
UL13 or mutated VP16.
Unfortunately, packaging using mutated VP16 lowered the
titers ~100-fold, and packaging using both mutated VP16
and other mutated HSV-1 proteins further lowered the tit-
ers to levels that cannot support in vivo gene transfer exper-
iments. To improve the titers, and to explore the
mechanism by which VP16 reduces long-term expression,
we examined the effects on recombinant gene expression of
two HSV-1 proteins, UL46 and UL47, that modulate the
activity of VP16 [16-18]. Vectors packaged using an HSV-1
cosmid set harboring a deletions of UL46, or UL47, or both,
supported both improved gene transfer and long-term
expression [19]. Vectors packaged using an HSV-1 cosmid
set harboring deletions in both UL46 and UL47 supported
larger improvements in recombinant gene expression com-
pared to vectors packaged using an HSV-1 cosmid set har-
boring a deletion of either gene alone. Also, packaging
using an HSV-1 cosmid set harboring the deletion of both
UL46 and UL47 supported higher titers than packaging
using a mutated VP16. Of note, a second approach to
improve the titers using mutated VP16 has been reported:
A recombinant HSV-1 vector containing a mutated VP16
was grown to high titer in the presence of equine herpesvi-
rus (EHV-1) gene 12 [20], the EHV-1 homolog of HSV-1
VP16. EHV-1 gene 12 transactivates HSV-1 promoters,
thereby restoring the titers to levels similar to those
obtained using wild type (wt) VP16. However, EHV-1 gene
12 is not incorporated into HSV-1 particles, so EHV-1 gene
12 is unlikely to reduce recombinant gene expression.
In the present study, we tested the hypothesis that specific
proteins in the HSV-1 particle act by multiple pathways to
reduce recombinant gene expression. We examined the
long-term expression supported by a HSV-1 vector that
contained a neuronal-specific promoter and was packaged
using an HSV-1 cosmid set harboring combinations of
mutated proteins that included UL13 and specific proteins
in the VP16 transcriptional complex. The preferred com-
bination was mutated UL13, UL46, and UL47, and this
packaging condition improved both gene transfer and
long-term expression.BMC Molecular Biology 2009, 10:58 http://www.biomedcentral.com/1471-2199/10/58
Page 3 of 11
(page number not for citation purposes)
Results
HSV-1 vectors packaged using specific combinations of 
mutated HSV-1 proteins
In this study, we tested the hypothesis that specific pro-
teins in the HSV-1 particle act by multiple pathways to
reduce recombinant gene expression. We packaged pNFH-
lac [7], which contains the neurofilament heavy gene (NF-
H) promoter, using two combinations of mutated HSV-1
proteins that included a point mutation in UL13 (UL13g,
abolishes protein kinase activity [14]) and a mutated pro-
tein in the VP16 transcriptional complex, either a linker
insertion mutation in VP16 (VP16in14 [21,22]) or a dele-
tion of both UL46 and UL47 (ΔUL46/47 [16,17,19]). Pack-
agings that used VP16in14 also contained EHV-1 gene 12
to improve the titers [20]. Control packaging conditions
included i) UL13g, ii) VP16in14 and EHV-1 gene 12, iii)
ΔUL46/47, or iv) standard conditions (wt, no mutated
HSV-1 proteins), as the negative control. The numbers of
infectious vector particles (IVP/ml) in these vector stocks
were determined by 5-bromo-4-chloro-3-indoyl-β-D-
galactopyranoside (X-gal) staining at 24 hours after trans-
duction of baby hamster kidney (BHK) fibroblast cells.
The results (Table 1) showed that pNFHlac/vp16in14,
gene12, ul13g (nomenclature, vector followed by the
mutated proteins used in packaging) reduced the titers
7.2-fold, and the other packaging conditions supported
titers that were similar (≤ 3-fold reduction) to those
obtained using standard packaging conditions (pNFHlac/
wt). Next, we determined the titers of vector genomes
(VG/ml); we isolated DNA from the vector stocks and per-
formed PCR using primers from the Lac Z gene [14]. As a
measure of the packaging efficiency, we calculated the
ratio of the physical titer to the biological titer (VG/IVP)
for each vector stock. The results (Table 1) showed that
packaging pNFHlac in the presence of any of these
mutated HSV-1 proteins, alone or in combination,
resulted in similar ratios of the physical titer to the biolog-
ical titer compared to packaging using standard condi-
tions. Thus, these mutated HSV-1 proteins, alone or in
specific combinations, did not cause large changes in the
packaging efficiency.
The levels of long-term expression supported by HSV-1 
vectors packaged using specific combinations of mutated 
HSV-1 proteins
These vector stocks were microinjected into the striatum,
the rats were sacrificed 4 days, or 2 weeks, or 1, 2, or 3
months after gene transfer, and X-gal staining was per-
formed. Control rats that received PBS lacked X-gal posi-
tive striatal cells, but faint X-gal staining was observed in
small numbers of cells that lined the brain vasculature
(not shown). Sections from rats sacrificed at 4 days after
gene transfer with each of these vector stocks contained
numerous X-gal positive cells proximal to the injection
sites. High power views revealed that some of these cells
contained neuronal morphology, including positive cell
bodies with proximal processes, and more distal positive
processes that did not appear to be associated with a cell
body were also observed (pNFHlac/ul13g, Figure 1A;
pNFHlac/VP16in14, gene12, Figure 1D; pNFHlac/
Δul46&47, ul13g, Figure 1G; pNFHlac/VP16in14, gene12,
ul13g, Figure 1J). HSV-1 is known to infect axon terminals
and be retrogradely transported to the cell body [23], and
small numbers of positive cells were observed at distant
sites, including specific areas of neocortex, that contain
neurons that project to the striatum (not shown). Subse-
quent analyses focused on the X-gal positive striatal cells,
the majority of the X-gal positive cells.
To determine the efficiency of gene transfer, we quantified
the number of positive cells at 4 days after gene transfer
divided by the amount of vector that was injected. To
quantify any changes in the efficiency of gene transfer
caused by packaging using specific mutated HSV-1 pro-
Table 1: The numbers of X-gal positive striatal cells from rats sacrificed at various times after microinjection of pNFHlac packaged 
using specific combinations of mutated HSV-1 proteins
Purified titersa Average X-gal positive cells per rat
Time after gene transfer
Relative efficiency of gene
transferb
Packaging condition VG/ml IVP/ml VG/IVP 4 days 2 wks 1 month 2 months 3 months
cΔul46&47, ul13g 6.4 × 107 5.0 × 106 10.1 1023 ± 23 680 ± 49 480 ± 11 319 ± 5 155 ± 30 5.7
VP16in14, gene12, ul13g 7.6 × 106 7.2 × 105 10.1 201 ± 8 119 ± 9 65 ± 6 44 ± 4 23 ± 6 2.3
VP16in14, gene12 1.2 × 107 1.8 × 106 6.7 343 ± 17 104 ± 4 65 ± 15 36 ± 8 16 ± 2 1.6
ul13g 2.0 × 107 1.8 × 106 11.1 393 ± 17 197 ± 6 99 ± 16 47 ± 19 19 ± 5 1.8
Δul46&47d 3.1 × 107 3.0 × 106 10 2,532 ± 93 980 ± 88 616 ± 58 315 ± 17 92 ± 11 9.9
wtd 6.3 × 107 5.2 × 106 12 445 ± 39 63 ± 9 12 ± 2 0 ± 0 0 ± 0 1.0
Three rats were analyzed for condition and time point; the means ± SDs are shown.
aThe titers of each vector stock after purification and concentration. VG/ml is vector genomes/ml; IVP/ml is infectious vector particles/ml.
bThe efficiency of gene transfer is the number of positive cells at 4 days/the amount of vector injected. The relative efficiency of gene transfer is the 
efficiency of gene transfer with a specific condition/the efficiency of gene transfer with wt packaging.
cVector stock diluted 3.3-fold before gene transfer.
dFor these two packaging conditions, the titers and the X-gal cell counts for 4 days through 2 months were previously reported in [19] and are 
included here only to support comparisons. The X-gal cell counts at 3 months have not been previously reported.BMC Molecular Biology 2009, 10:58 http://www.biomedcentral.com/1471-2199/10/58
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tein(s), we compared the efficiencies of gene transfer sup-
ported by pNFHlac packaged using specific mutated HSV-
1 protein(s) to the efficiency of gene transfer supported by
pNFHlac/wt (relative efficiency of gene transfer). Addi-
tionally, this ratio should correct for any underestimation
of the titers of these vector stocks due to the use of fibrob-
last cells in the tittering (see methods). The results (Table
1) showed that pNFHlac/Δul46&47, ul13g supported a
5.7-fold increase in the relative efficiency of gene transfer,
and we previously observed that pNFHlac/Δul46&47 sup-
ported a 9.9-fold increase [19]. Vector stocks that were
packaged using either VP16in14, gene12 or ul13g, or
both, supported modest, if any, increases in the efficiency
of gene transfer, similar to previous results from packag-
ings that used either VP16in14 or ul13g [14]. In compar-
ing two specific packaging conditions, the efficiency of
X-gal positive striatal cells from rats that received microinjections of pNFHlac packaged using specific combinations of mutated  HSV-1 proteins Figure 1
X-gal positive striatal cells from rats that received microinjections of pNFHlac packaged using specific combi-
nations of mutated HSV-1 proteins. The rats were sacrificed at 4 days, 2 months, or 3 months after gene transfer. A-C. 
pNFHlac/ul13g; 4 days after gene transfer (A), 2 months (B), and 3 months (C). D-F. pNFHlac/VP16in14, gene12; 4 days (D), 2 
months (E), and 3 months (F). G-I. pNFHlac/Δul46&47, ul13g; 4 days (G), 2 months (H), and 3 months (I). J-L. pNFHlac/
VP16in14, gene12, ul13g; 4 days (J), 2 months (K), and 3 months (L). These high power views show X-gal positive cell bodies 
and proximal processes. Scale bar: 25 μm.BMC Molecular Biology 2009, 10:58 http://www.biomedcentral.com/1471-2199/10/58
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gene transfer in the striatum may not correlate with the tit-
ers obtained using cultured fibroblast cells because of spe-
cific aspects of striatal anatomy and physiology, such as
the extracellular matrix, that are absent from the cultures
of fibroblast cells.
To quantify long-term expression, we compared the num-
bers of X-gal positive cells at 2 weeks, or 1, 2, or 3 months
after gene transfer to the numbers of positive cells at 4
days. This comparison should be independent of any var-
iability in either the titering procedure or the gene transfer
process, because this calculation uses the number of posi-
tive cells at 4 days for the initial value in the comparison.
For the control condition, pNFHlac/wt, by 2 weeks after
gene transfer the numbers of X-gal positive cells had
declined to 14% of the numbers of positive cells observed
at 4 days, by 1 month the number of positive cells was
<3% of that at 4 days, and at 2 or 3 months no positive
cells were observed (Table 1, Figure 2). {The data using
pNFHlac/wt and pNFHlac/Δul46&47, from 4 days
through 2 months, was collected in parallel with another
study and has been previously reported [19].} The decline
in expression we observed with pNFHlac/wt is similar to
that we have reported in two previous studies that exam-
ined pNFHlac/wt [1,7].
Vector stocks that were packaged using each of the three
mutated HSV-1 proteins alone supported X-gal positive
cells at 2 or 3 months after gene transfer (pNFHlac/ul13g,
Figure 1B and 1C; pNFHlac/VP16in14, gene12, Figure 1E
and 1F), times when no positive cells were observed using
pNFHlac/wt. Cell counts showed that packaging using
each of the three mutated HSV-1 proteins alone supported
increases in % of X-gal positive cells at 2 weeks, or 1, 2, or
3 months after gene transfer compared to pNFHlac/wt
(Table 1, Figure 2). At 2 weeks after gene transfer, the sta-
bilities of expression supported by these 3 packaging con-
ditions ranged from ~30 to 50%, but these 3 packaging
conditions supported similar stabilities of expression at 1,
2, or 3 months. The stabilities of expression observed
using pNFHlac/ul13g or pNFHlac/VP16in14, gene12 were
similar to those observed in a previous study that used
pNFHlac/ul13g or pNFHlac/VP16in14 [14].
The two stocks of pNFHlac that were prepared using specific
combinations of mutated HSV-1 proteins supported X-gal
positive cells at 2 or 3 months after gene transfer (pNFHlac/
Δul46&47, ul13g, Figure 1H and 1I; pNFHlac/VP16in14,
gene12, ul13g, Figure 1K and 1L). Interestingly, the two vec-
tor stocks that were packaged using specific combinations of
mutated HSV-1 proteins supported higher percentages of
long-term expression than those supported by pNFHlac
packaged using each of the mutated HSV-1 proteins alone
(Table 1, Figure 2). pNFHlac/Δul46&47, ul13g supported
somewhat higher percentages of long-term expression than
pNFHlac/VP16in14, gene12, ul13g at each of the time points
examined. Nonetheless, the percentages of long-term expres-
sion exhibited declines during the period that was examined
(2 weeks to 3 months) for each packaging condition (Table
1, Figure 2).
We determined the statistical significance of the changes
in the percentages of long-term expression using a two
way analysis of variance (ANOVA). The ANOVA showed a
statistically significant effect of packaging condition (p <
0.001). Subsequent pairwise comparisons showed that
the pNFHlac/Δul46&47, ul13g condition supported sig-
nificantly higher levels of long-term expression compared
to each of the other five conditions, including pNFHlac/
VP16in14, gene12, ul13g, at each of the four time points
(12 of these 20 comparisons p < 0.001; 6 of the compari-
sons p < 0.05; 1 comparison p = 0.056; 1 comparison p >
0.10). Also, subsequent pairwise comparisons suggested
that the pNFHlac/VP16in14, gene12, ul13g condition
supported higher levels of long-term expression com-
pared to each of the three conditions that used a single
mutated HSV-1 protein, at each of the four time points (7
of these 12 comparisons p < 0.05; 4 of the comparisons p
< 0.10; 1 comparison p > 0.10). Additionally, the ANOVA
showed a statistically significant effect of time (p < 0.001).
Subsequent pairwise comparisons showed that the per-
centages of long-term expression declined for comparing
each time point to the previous time point, for each pack-
aging condition (p < 0.05).
The stabilities of expression in the striatum supported by  pNFHlac packaged using specific combinations of mutated  HSV-1 proteins Figure 2
The stabilities of expression in the striatum sup-
ported by pNFHlac packaged using specific combina-
tions of mutated HSV-1 proteins. For each time point 
and packaging condition, the graph shows the % of X-gal pos-
itive cells at 4 days (mean number of X-gal positive cells at 2 
weeks, or 1, 2, or 3 months after gene transfer divided by the 
mean number of positive cells at 4 days (× 100); calculated 
using the data in Table 1).BMC Molecular Biology 2009, 10:58 http://www.biomedcentral.com/1471-2199/10/58
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The levels of neuronal-specific expression supported by 
these vector stocks
Because a specific altered vector particle might potentially
support a different cell type specificity of transduction
and/or expression than wt vector particles, we confirmed
that each of these vector stocks targeted expression to neu-
rons. We performing double staining using antibodies
against either E. coli β-galactosidase (β-gal) or a neuronal
marker, NeuN, on rats sacrificed at 4 days after gene trans-
fer (Table 2; pNFHlac/Δul46&47, ul13g, Figure 3A–C;
pNFHlac/VP16in14, gene12, ul13g, Figure 3G–I). Addi-
tionally, to establish long-term, neuronal-specific expres-
sion, we performed the same assay on rats that received
either pNFHlac/Δul46&47, ul13g or pNFHlac/VP16in14,
gene12, ul13g and were sacrificed at 2 months after gene
transfer (Figure 3D–F and 3J–L, Table 2). Cell counts
showed that each of these vector stocks supported ~90%
neuronal specific expression at 4 days after gene transfer,
and pNFHlac packaged using each combination of
mutated HSV-1 proteins supported ~90% neuronal spe-
cific expression at 2 months after gene transfer (Table 2).
Discussion
HSV-1 gene expression is hypothesized to shut off recom-
binant gene expression from HSV-1 vectors. However,
using this helper virus-free HSV-1 vector system, expres-
sion from many promoters remains short-term, even
though this vector system does not contain any HSV-1
genes. To resolve this paradox, we hypothesized that spe-
cific HSV-1 proteins in the vector particle shut off recom-
binant gene expression; in support of this hypothesis, we
previously reported that packaging using specific mutated
HSV-1 proteins improves long-term expression [14].
These results suggested the hypothesis that specific pro-
teins in the HSV-1 particle act by multiple pathways to
reduce recombinant gene expression; thus, interfering
with multiple pathways might support higher levels of
recombinant gene expression than those obtained by
interfering with a specific single pathway. The data in this
study support this hypothesis and suggest that multiple
HSV-1 proteins act together to shut off recombinant gene
expression by at least two different pathways. One path-
way contains the UL13 protein kinase, and a second path-
way contains the VP16 transcriptional complex. Of note,
the preferred packaging condition was pNFHlac packaged
using mutated UL13, UL46, and UL47.
Titers
Vector particles produced by packaging using a specific
mutated HSV-1 protein(s) might have a reduced capabil-
ity to bind to and/or enter cells. A reduction in the trans-
duction efficiency would likely be detected as an increased
ratio of vector genomes (VG) to biological titer (infectious
vector particles (IVP)), for a specific packaging condition.
In contrast, the VG/IVP ratio was similar for the standard
condition (pNFHlac/wt) and each packaging condition
that used a mutated HSV-1 protein, including the two
conditions that used specific combinations of mutated
HSV-1 proteins. Thus, the vector particles produced by
these different packaging conditions appear to have simi-
lar transduction efficiencies. Similarly, we previously
found that packaging vectors in the presence of mutations
in each of seven different HSV-1 proteins (UL13, vhs,
UL46, UL47, VP16, US3, or US11) did not affect the trans-
duction efficiency [14,19].
The two vector stocks that were prepared using specific
combinations of mutated HSV-1 proteins contained suffi-
cient titers to support gene transfer into the rat brain. When
used individually, the mutated UL13 had modest effects on
the titers, and the mutated UL46 and UL47 had little or no
effects on the titers, in either vector packaging or the growth
of HSV-1 viruses that contain each mutation [14,16,17].
Consistent with these observations, the pNFHlac/
Δul46&47, ul13g condition supported titers that were sim-
ilar to the standard packaging condition (pNFHlac/wt). In
contrast, packaging pNFHlac in the presence of a mutated
VP16 reduced the titers ~100-fold [14], and a HSV-1 virus
that contained this mutated VP16 displayed reduced
growth [22]. Use of EHV-1 gene 12 was previously shown
to improve the growth of HSV-1 viruses that contain a
mutated VP16 [20]. Analogous to those results, pNFHlac
packaged using both a mutated VP16 and EHV-1 gene 12,
and either wt or mutated UL13, yielded titers that were
within an order of magnitude of the titers obtained using
the standard packaging condition.
Improved gene expression from pNFHlac packaged using 
combinations of mutated HSV-1 proteins
We previously found that packaging pNFHac in the pres-
ence of either a mutated UL13 or specific components of
the VP16 transcriptional complex improved long-term
expression [14,19]. There is no known interaction
between UL13 and the VP16 transcriptional complex.
Thus, these observations suggested the hypothesis that
there are at least two pathways by which specific proteins
in the HSV-1 particle reduce recombinant gene expres-
sion. Thus, packaging vectors in the presence of both
mutated UL13 and a mutated component of the VP16
complex would further improve long-term expression,
compared to previous results [14,19].
The results of this study support this hypothesis. pNFHlac
packaged using either of two combinations of mutated
proteins that included both mutated UL13 and a mutated
component of the VP16 complex supported higher levels
of long-term expression than the levels supported by
pNFHlac packaged using any of these mutated HSV-1 pro-
teins, individually. The longest time point examined in
this study was 3 months, because that time was sufficientBMC Molecular Biology 2009, 10:58 http://www.biomedcentral.com/1471-2199/10/58
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β-gal-IR positive striatal cells that also contain NeuN-IR from rats sacrificed at 4 days or 2 months after gene transfer with  pNFHlac packaged using specific combinations of mutated HSV-1 proteins Figure 3
-gal-IR positive striatal cells that also contain NeuN-IR from rats sacrificed at 4 days or 2 months after gene 
transfer with pNFHlac packaged using specific combinations of mutated HSV-1 proteins. β-gal-IR was detected 
using a rabbit anti-E. coli β-gal antibody, and was visualized using a fluorescein isothiocyanate-conjugated goat anti-rabbit IgG. In 
the same sections, NeuN-IR was detected using a mouse monoclonal anti-NeuN, and was visualized using a rhodamine isothi-
ocyanate-conjugated goat anti-mouse IgG. NeuN is a neuronal marker found in the nucleus. A-C. pNFHlac/Δul46&47, ul13g, 
rat sacrificed at 4 days; β-gal-IR (A), NeuN-IR (B), merged (C). Many of the β-gal-IR cells also contain NeuN-IR. D-F. pNFHlac/
Δul46&47, ul13g, rat sacrificed at 2 months; β-gal-IR (D), NeuN-IR (E), merged (F). G-I. pNFHlac/VP16in14, gene12, ul13g, rat 
sacrificed at 4 days; β-gal-IR (G), NeuN-IR (H), merged (I). J-L. pNFHlac/VP16in14, gene12, ul13g, rat sacrificed at 2 months; β-
gal-IR (J), NeuN-IR (K), merged (L). M-O. pNFHlac/VP16in14, gene12, ul13g, rat sacrificed at 4 days; no primary antibodies. 
Scale bar: 25 μm.BMC Molecular Biology 2009, 10:58 http://www.biomedcentral.com/1471-2199/10/58
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to establish improved long-term expression; however, we
have previously shown that HSV-1 vectors support long-
term expression for at least 14 months [2]. Interestingly,
pNFHlac/Δul46&47, ul13g supported a higher level of
long-term expression than pNFHlac/VP16in14, gene12,
ul13g. This observation is difficult to explain in the
absence of more detailed mechanistic information about
how UL46, UL47, and VP16 interact. pNFHlac/Δul46&47,
ul13g also improved the efficiency of gene transfer, con-
sistent with previous results with pNFHlac/Δul46&47.
The capability of more complex packaging conditions to
further improve recombinant gene expression, as shown
here, is encouraging for future approaches to obtain addi-
tional improvements in expression.
Potential mechanisms that reduce recombinant gene 
expression from HSV-1 vectors
Currently available information suggests that UL13 and
VP16 may act by different mechanisms to reduce recom-
binant gene expression. In regards to UL13: Substrates for
UL13 include a number of HSV-1 proteins (ICP0, ICP22,
gE, and VP22 (UL49) [24-27]) and at least two cellular
proteins, elongation factor 1δ [28] and RNA polymerase II
[29,30]. UL13 and cdc2 target the same site in elongation
factor 1δ [31]. In regards to VP16: The HSV-1 oris fragment
in pNFHlac contains the immediate early (IE) 4/5 pro-
moter and adjacent TAATGARAT elements [7], binding
sites for the VP16 transcriptional complex [32]. Although
pNFHlac contains three polyadenylation sites between
the IE and NFH promoters, increased transcription from
the IE 4/5 promoter might interfere with transcription
from the NF-H promoter. Alternatively, wt HSV-1, but not
in1814, activates the c-jun N-terminal kinase/stress-acti-
vated protein kinase [33], raising the possibility that this
signaling pathway might reduce the activity of the NF-H
promoter in pNFHlac.
Although packaging using both a mutated UL13 and a
mutated component of the VP16 transcriptional com-
plex improved recombinant gene expression, the levels
of expression still declined over time, suggesting that
additional, as yet unknown, factors contribute the
decline in expression. The tegument in the HSV-1 virus
particle contains ~15 proteins, and 7 of these proteins
have been examined for effects on recombinant gene
expression. Two tegument proteins had minimal effects
on expression, and specific mutations in each of five teg-
ument proteins improved the efficiency of gene transfer
and/or long-term expression [14,19]. It remains to be
determined if other tegument proteins affect recom-
binant gene expression. Other potential factors that
might reduce recombinant gene expression include spe-
cific proteins in the HSV-1 vector particle capsid or enve-
lope, or the transduction–vector particle disassembly
(uncoating) process may be detected by specific cellular
signaling pathways.
Conclusion
In conclusion, the preferred combination of mutated
HSV-1 proteins was mutated UL13, UL46, and UL47. Vec-
tors packaged using this combination of mutated proteins
supported a higher efficiency of gene transfer and high
levels expression for 3 months, the longest time exam-
ined. These advances will benefit specific gene therapy
applications of HSV-1 vectors.
Methods
Materials
Restriction endonucleases were obtained from New England
Biolabs and Roche. G418, Dulbecco's modified minimal
essential medium, fetal bovine serum, OPTI-MEM I, and
lipofectamine were obtained from Invitrogen. X-Gal was
purchased from Sigma. Rabbit anti-E. coli β-gal antibody was
purchased from ICN, and mouse monoclonal anti-NeuN
[34] was from Chemicon. Fluorescein isothiocyanate-conju-
gated goat anti-rabbit immunoglobulin (Ig) G and rhodam-
ine isothiocyanate-conjugated goat anti-mouse IgG were
from Jackson ImmunoResearch Laboratories.
Table 2: The numbers of  -gal-IR positive cells that costain for NeuN-IR from rats sacrificed at 4 days or 2 months after microinjection 
of pNFHlac packaged using specific combinations of mutated HSV-1 proteins
Packaging
condition
Time after
gene transfer
Total β-gal-IR
positive cells
β-gal-IR and NeuN-IR positive cells % costained
cells
Δul46&47, ul13g 4 days 199 180 90
Δul46&47, ul13g 2 months 110 98 89
VP16in14, gene12, ul13g 4 days 200 181 91
VP16in14, gene12, ul13g 2 months 78 69 88
VP16in14, gene12 4 days 205 190 93
Δul46&47 4 days 195 179 92
ul13g 4 days 211 189 90
wt 4 days 198 176 89
β-gal-IR was detected using a rabbit anti-E. coli β-gal antibody that was visualized with a fluorescein isothiocyanate-conjugated goat anti-rabbit IgG, 
and NeuN-IR was detected in the same sections using a mouse monoclonal anti-NeuN antibody that was visualized with a rhodamine 
isothiocyanate-conjugated goat anti-mouse IgG.BMC Molecular Biology 2009, 10:58 http://www.biomedcentral.com/1471-2199/10/58
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Vectors, plasmids, and cosmids
pNFHlac [7] contains the mouse NF-H promoter (0.6 kb
fragment [35]). pNFHlac supports only short-term expres-
sion following packaging using standard conditions (no
mutated HSV-1 proteins); rats sacrificed at 4 days after
gene transfer contained many X-gal positive cells, but few,
if any, positive cells were observed in rats sacrificed at 1 or
2 months [1,7]. Plasmid pC12 contains EHV-1 gene 12
under the control of the cytomegalovirus IE promoter
([20] gift from Dr. Coffin).
Cosmid set C (cos6, cos14, cos28, cos48, cos56, [36]) rep-
resents the HSV-1 genome, and the a  sequence was
deleted from the two cosmids that contain it (cos6Δa,
cos48Δa [12]). cos6Δa/ul13g [14] contains a point muta-
tion in UL13 that abolishes protein kinase activity [14];
HSV-1 particles contain UL13 [27,37]. cos56/vp16in14
[14] contains a linker insertion mutation in VP16 [21,22]
that abolishes enhancer activity but supports assembly of
HSV-1 particles. cos56/Δul46/47 [19] contains a deletion
of both UL46 and UL47 [17]; UL46 and UL47 are compo-
nents of VP16 transcriptional complex and are present in
HSV-1 particles [16,17,32].
Cells, vector packaging, and titering
The culture conditions for BHK21 cells or 2-2 cells [38] have
been described [14]. Helper virus-free packaging [12] was
performed using a modified protocol [39] that improves the
titers and cosmids that contain specific mutated HSV-1 pro-
teins, or no mutated HSV-1 proteins (standard or wt condi-
tions). Packaging procedures that used EHV-1 gene 12
employed the standard DNA transfection conditions [12,39]
with a 1:1 (μg:μg) ratio of pNFHlac and pC12 [20]. Packag-
ing using VP16in14 reduces the titers ~100-fold [14], and
EHV-1 gene 12 was added to improve the titers. Vector stocks
were purified as described [40].
The titers of vector genomes (VG)/ml were determined by
extracting DNA from the vector stocks and determining
the amounts of pNFHlac DNA using PCR and primers that
recognize the Lac Z gene [14]. The titers of infectious vec-
tor particles (IVP)/ml were determined by quantifying the
numbers of X-gal positive cells at 1 day after transduction
of BHK cells [14]. Expression from the NF-H promoter (in
pNFHlac) in BHK fibroblast cells is ectopic expression,
and this ectopic expression declines at longer times after
gene transfer [1,14]. We used this fibroblast cell line rather
than a neuronal cell line, such as PC12 cells, because we
previously found that titering pNFHlac stocks on PC12
cells results in lower titers compared to those obtained on
BHK fibroblast cells [1,14], possible because PC12 cells
do not form a monolayer that facilitates efficient trans-
duction and accurate titering. wt HSV-1 was not observed
in these vector stocks (<10 plaque forming units/ml).
Expression experiments in the rat brain
These studies were approved by the W. Roxbury VA Hos-
pital IACUC. Stereotactic injections (3 μl/site, 2 sites)
were used to deliver vector stocks into the striatum of
male Sprague Dawley rats (150–175 gm; anterior-poste-
rior (AP) +0.8, medial-lateral (ML) +2.5, dorsal-ventral
(DV) -5.5; AP +0.8, ML -2.5, DV -5.5). AP is relative to
bregma, ML is relative to the sagittal suture, and DV is rel-
ative to the bregma-lambda plane [41]. Vector stocks were
injected using a micropump (model 100, KD Scientific); 3
μl of vector stock was injected over 8 minutes, the needle
was maintained in place for an additional 5 minutes, and
the needle was slowly withdrawn over approximately 5
minutes. At 4 days to 3 months after gene transfer, the rats
were perfused, the brains were sectioned, and X-gal stain-
ing was performed [1] at room temperature, pH 7.9, for 3
hours. Alternatively, to localize β-gal to neurons, rabbit
anti-E. coli β-gal was visualized with a fluorescein isothio-
cyanate-conjugated goat anti-rabbit IgG, and mouse mon-
oclonal anti-NeuN was visualized with a rhodamine
isothiocyanate-conjugated goat anti-mouse IgG [1].
Cell counts
Coronal sections (25 μm) that included the striatum were
prepared. Every 4th section was analyzed for recombinant
gene expression, and ~12 of these sections contained
either the X-gal or the β-gal-immunoreactivity (IR) posi-
tive cells. Low power (10×) was used to identify the posi-
tive cells, and high power (40×) was used to perform the
cell counts. To verify the accuracy of the cell counts, each
section was counted at least two times, on different days,
and the values differed by <10% for each section. ANOVA
followed by multiple pairwise comparisons was used to
analyze the statistical significance of differences in the
numbers of X-gal cells.
Abbreviations
ANOVA: analysis of variance; AP: anterior-posterior; β-gal:
β-galactosidase; BHK: baby hamster kidney; DV: dorsal-
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immunoreactivity; IVP: infectious vector particles; LAT:
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neurofilament heavy gene; TH: tyrosine hydroxylase; VG:
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